The three yr results of a multicenter trial in de novo pediatric KT treated with a proliferative signal inhibitor and low dose CNI are presented. Thirty-seven children (9.1 ± 5 yr old) received basiliximab, cyclosporine A (CyA C2:1400 ng/mL), (MMF C0:1.5-3 μg/mL), and prednisone. Three wk later everolimus was started (C0:5-10 ng/mL), CyA was reduced (C2:600 ng/mL after 90 days 300 ng/mL), and MMF discontinued. During the three-yr period patient and graft survivals were 96%. One patient died for causes unrelated to the immunosuppression. Cumulative acute rejection rate including protocol and indication biopsies was 21.9%. None of the patients had signs of chronic humoral rejection. Incidence of dnDSA was 5%, 11%, and 22% at one, two, and three yr post-transplant, respectively. Mean glomerular filtration rate measured at one yr and three yr post-transplant was 105.5 ± 31 and 110.7 ± 27 mL/min/1.73 m2, respectively. A growth velocity of 7.7 ± 6.7 cm/yr was achieved with positive catch-up growth. No malignancy or post-transplant lymphoproliferative diseases were diagnosed. In conclusion, the treatment based on basiliximab induction, everolimus, low-dose cyclosporine, and low-dose prednisone leads to good long-term efficacy in de novo pediatric KT recipients.
Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients / M. Ferraresso, M. Belingheri, F. Ginevri, L. Murer, L. Dello Strologo, M. Cardillo, A. Parodi, G. Ghirardo, I. Guzzo, A. Innocente, L. Ghio. - In: PEDIATRIC TRANSPLANTATION. - ISSN 1397-3142. - 18:4(2014 Feb), pp. 350-356.
|Titolo:||Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients|
FERRARESSO, MARIANO (Primo)
|Settore Scientifico Disciplinare:||Settore MED/18 - Chirurgia Generale|
Settore MED/14 - Nefrologia
|Data di pubblicazione:||feb-2014|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1111/petr.12261|
|Appare nelle tipologie:||01 - Articolo su periodico|